a protein of the p53 family of proteins. p73, like p53, may have tumor suppressor activity, but its multiple isoforms possess different and sometimes opposing functions. Participates in the apoptotic response to DNA damage. Phosphorylated in a cell cycle-dependent manner and negatively regulated by CDKs. When overproduced, activates transcription from p53-responsive promoters and induces apoptosis. Nine transactivation competent (TA) or dominant negative (DN) isoforms, derived from alternative-splicing and alternative promoters, have been described. NH2-terminally truncated p73 isoforms (DNp73) may be oncogenic. DNp73 is elevated in a number of cancers and is associated with adverse clinical outcomes and resistance to chemotherapy. The C-terminal oligomerization domain binds to the ABL1 tyrosine kinase SH3 domain. Isoform Beta interacts homotypically and with p53/TP53, whereas isoform Alpha does not. Isoform Gamma interacts homotypically and with all p73 isoforms. Isoform Delta interacts with isoform Gamma, isoform Alpha, and homotypically. Isoforms Alpha and Beta interact with HIPK2. Isoform Alpha interacts with RANBP9; forms complex with p53 and CABLES1. Isoform Beta interacts with WWOX; interacts with HECW2. Note: This description may include information from UniProtKB.
Molecular Function: identical protein binding; protein binding; p53 binding; metal ion binding; double-stranded DNA binding; damaged DNA binding; chromatin binding; protein kinase binding; transcription factor activity; transcription factor binding
Biological Process: transcription from RNA polymerase II promoter; G1 DNA damage checkpoint; cerebrospinal fluid secretion; positive regulation of cell size; activation of MAPK activity; positive regulation of transcription, DNA-dependent; regulation of mitotic cell cycle; negative regulation of transcription from RNA polymerase II promoter; post-embryonic development; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; negative regulation of cardiac muscle cell proliferation; response to gamma radiation; negative regulation of neuron apoptosis; positive regulation of oligodendrocyte differentiation; kidney development; inflammatory response; cell cycle arrest; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; protein tetramerization; response to X-ray; negative regulation of JNK activity; release of cytochrome c from mitochondria; mismatch repair; hippocampus development; digestive tract morphogenesis; response to organic nitrogen; negative regulation of neuron differentiation; DNA damage response, signal transduction resulting in induction of apoptosis; regulation of gene expression; neuron development; positive regulation of transcription from RNA polymerase II promoter; response to DNA damage stimulus
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.